289 related articles for article (PubMed ID: 3120987)
21. Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses.
Fenton AJ; Gutteridge DH; Kent GN; Price RI; Retallack RW; Bhagat CI; Worth GK; Thompson RI; Watson IG; Barry-Walsh C
Clin Endocrinol (Oxf); 1991 Mar; 34(3):197-204. PubMed ID: 2036728
[TBL] [Abstract][Full Text] [Related]
22. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of intravenous pamidronate in Paget's disease of bone.
Grauer A; Klar B; Scharla SH; Zieglar R
Semin Arthritis Rheum; 1994 Feb; 23(4):283-4. PubMed ID: 8009261
[No Abstract] [Full Text] [Related]
24. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
[TBL] [Abstract][Full Text] [Related]
25. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
26. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
27. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
28. [Amino-hydroxy-propylidene biphosphonate in the treatment of Paget's disease resistant to calcitonin and/or etidronate].
Miravet L; Kuntz D
Rev Rhum Mal Osteoartic; 1989 Mar; 56(4):287-92. PubMed ID: 2496460
[TBL] [Abstract][Full Text] [Related]
29. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment.
Papapoulos SE; Frolich M; Mudde AH; Harinck HI; vd Berg H; Bijvoet OL
J Clin Endocrinol Metab; 1987 Jul; 65(1):89-94. PubMed ID: 3495547
[TBL] [Abstract][Full Text] [Related]
30. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K
Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
[TBL] [Abstract][Full Text] [Related]
31. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
Papapoulos SE; Frölich M
J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
[TBL] [Abstract][Full Text] [Related]
32. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium.
Price RI; Gutteridge DH; Stuckey BG; Kent GN; Retallack RW; Prince RL; Bhagat CI; Johnston CA; Nicholson GC; Stewart GO
J Bone Miner Res; 1993 Feb; 8(2):209-17. PubMed ID: 8442439
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Paget's bone disease with the bisphosphonate APD.
Mautalen CA
Henry Ford Hosp Med J; 1983; 31(4):244-8. PubMed ID: 6425243
[No Abstract] [Full Text] [Related]
34. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
[TBL] [Abstract][Full Text] [Related]
36. [Moderate Paget's disease treated with pamidronate (APD): experience in 43 patients with a single 60 mg infusion of varying duration of 1-to-24 hours].
Thiébaud D; Portmann L; Burckhardt P
Schweiz Med Wochenschr; 1992 Dec; 122(49):1889-94. PubMed ID: 1462150
[TBL] [Abstract][Full Text] [Related]
37. Aminohexane diphosphonate in the treatment of Paget's disease of bone.
Atkins RM; Yates AJ; Gray RE; Urwin GH; Hamdy NA; Beneton MN; Rosini S; Kanis JA
J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614
[TBL] [Abstract][Full Text] [Related]
38. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate.
Papapoulos SE; Hoekman K; Löwik CW; Vermeij P; Bijvoet OL
J Bone Miner Res; 1989 Oct; 4(5):775-81. PubMed ID: 2816519
[TBL] [Abstract][Full Text] [Related]
39. Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy.
Eekhoff ME; Zwinderman AH; Haverkort DM; Cremers SC; Hamdy NA; Papapoulos SE
Bone; 2003 Nov; 33(5):831-8. PubMed ID: 14623059
[TBL] [Abstract][Full Text] [Related]
40. Clinical experience with the use of two diphosphonates in the treatment of Paget's disease.
Dewis P; Prasad BK; Anderson DC; Willets S
Ann Rheum Dis; 1985 Jan; 44(1):34-8. PubMed ID: 3918513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
